CAS 33564-30-6|Cefoxitin sodium

Introduction:Basic information about CAS 33564-30-6|Cefoxitin sodium, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameCefoxitin sodium
CAS Number33564-30-6Molecular Weight449.434
Density/Boiling Point843.4ºC at 760 mmHg
Molecular FormulaC16H16N3NaO7S2Melting Point>160°C
MSDSChineseUSAFlash Point463.9ºC
Symbol
GHS07
Signal WordWarning

Names

NameCefoxitin Sodium Salt
SynonymMore Synonyms

Cefoxitin sodium BiologicalActivity

DescriptionCefoxitin sodium (MK-306) is a cephamycin antibiotic, often grouped with the second generation cephalosporins, acts by interfering with cell wall synthesis, its activity spectrum includes a broad range of gram-negative and gram-positive bacteria.
Related CatalogSignaling Pathways >>Anti-infection >>BacterialResearch Areas >>Infection
References

[1]. Cavalli Z, et al. Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection. J Bone Jt Infect. 2018 Sep 7;3(4):182-186.

Chemical & Physical Properties

Boiling Point843.4ºC at 760 mmHg
Melting Point>160°C
Molecular FormulaC16H16N3NaO7S2
Molecular Weight449.434
Flash Point463.9ºC
Exact Mass449.032745
PSA204.63000
InChIKeyGNWUOVJNSFPWDD-XMZRARIVSA-M
SMILESCOC1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CSC21.[Na+]

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XI0330500
CHEMICAL NAME :
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7- methoxy-8-oxo-7-((2-thienylacetyl)amino)-, monosodium salt, (6R-cis)-
CAS REGISTRY NUMBER :
33564-30-6
LAST UPDATED :
199806
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C16-H16-N3-O7-S2.Na
MOLECULAR WEIGHT :
449.46
WISWESSER LINE NOTATION :
T46 ANV ES GUTJ CO1 G1OVZ HVO CMV1- BT5SJ &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
100 mg/kg/2D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - interstitial nephritis
REFERENCE :
SMJOAV Southern Medical Journal. (Southern Medical Assoc., POB 2446, Birmingham, AL 35205) V.1- 1908- Volume(issue)/page/year: 80,274,1987
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
229 mg/kg/4D-I
TOXIC EFFECTS :
Blood - normocytic anemia Blood - aplastic anemia
REFERENCE :
DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 17,816,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 22,123,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 31,629,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8580 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 11,181,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 31,629,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 31,629,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
4970 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 22,291,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
10000 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,410,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
63 gm/kg/21D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - weight loss or decreased weight gain Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 26(Suppl 1),185,1978 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3879 No. of Facilities: 448 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 20341 (estimated) No. of Female Employees: 15900 (estimated)

Safety Information

Symbol
GHS07
Signal WordWarning
Hazard StatementsH317
Precautionary StatementsP280
Personal Protective Equipmentdust mask type N95 (US);Eyeshields;Faceshields;Gloves
Hazard CodesXn:Harmful
Risk PhrasesR36/37/38;R42/43
Safety PhrasesS22-S26-S36/37/39
RIDADRUN 3077
WGK Germany3
RTECSXI0330500
Packaging GroupIII
Hazard Class9
HS Code3004201990

Customs

HS Code3004201990

Articles30

More Articles
Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model.

J. Antimicrob. Chemother. 69(6) , 1599-607, (2014)

Mycobacterium abscessus is known to be the most drug-resistant Mycobacterium and accounts for ∼80% of pulmonary infections caused by rapidly growing mycobacteria. This study reports a new Drosophila m...

Evaluation of cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate, and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme for recovery of Clostridium difficile isolates from fecal samples.

J. Clin. Microbiol. 51(9) , 3094-6, (2013)

Cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate (CCFA-HT), and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme (CCMB-TAL) were compared for recov...

Isolation of Clostridium difficile from faecal specimens--a comparison of chromID C. difficile agar and cycloserine-cefoxitin-fructose agar.

J. Med. Microbiol. 62(Pt 9) , 1423-7, (2013)

The culture of toxigenic Clostridium difficile from stool specimens is still seen as the gold standard for the laboratory diagnosis of C. difficile infection (CDI). bioMérieux have released ChromID Cd...

Synonyms

Sodium (6R,7S)-3-(Hydroxymethyl)-7-methoxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Carbamate (Ester)
EINECS 252-641-2
Cefoxitin sodium salt
sodium (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Merxin
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[[2-(2-thienyl)acetyl]amino]-, sodium salt, (6R,7S)- (1:1)
Betacef
Sodium (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Sodium (6R-cis)-3-((Carbamoyloxy)methyl)-7-methoxy-8-oxo-7-(2-thienylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Cefoxitin sodium
Cenomycin
Mefoxitin
(6R,7S)-3-[(carbamoyloxy)méthyl]-7-méthoxy-8-oxo-7-[(thiophén-2-ylacétyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate de sodium
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt, (6R,7S)-
Natrium-(6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylat
MFCD00079042
Cefoxitin (sodium)
CAS 31090-12-7|2-Mercapto-4-methyl-1,3-thiazol-5-yl-acetic acid
CAS 35607-66-0|Cefoxitin
Recommended......
TOP